Bayer Bigs Up Vitrakvi In Comparison With Roche's Rozlytrek
Two Tumor-Agnostic Therapies In ESMO Spotlight
Executive Summary
In the absence of head-to-head data, the results from a "matching-adjusted indirect comparison" suggest favorable efficacy of the German group's treatment for solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion when compared with competitor Rozlytrek from Roche.
You may also be interested in...
Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
Roche/Genentech Set Lower Rozlytrek Price To Catch Up With Bayer’s Vitrakvi
Entrectinib clinched double approvals in the US for ROS1-positive NSCLC and for tumors with NTRK gene fusions – making it the third tumor-agnostic and second NTRK-fusion approval in the US.
FDA Nod For Loxo/Bayer Tissue Agnostic Drug Marks Paradigm Shift In Cancer
Vitrakvi is effective against a wide variety of cancers driven by NTRK fusion. But finding the patients who will benefit will be a challenge, given there are expected to be only around 2,500 to 3,000 new cases in the US and testing for the mutation is uncommon.